KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Arbutus Biopharma (ABUS) over the last 15 years, with Q3 2025 value amounting to -$5.8 million.

  • Arbutus Biopharma's Cash from Operations rose 7194.73% to -$5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$45.3 million, marking a year-over-year increase of 3697.08%. This contributed to the annual value of -$64.8 million for FY2024, which is 2453.69% up from last year.
  • As of Q3 2025, Arbutus Biopharma's Cash from Operations stood at -$5.8 million, which was up 7194.73% from -$15.7 million recorded in Q2 2025.
  • Arbutus Biopharma's Cash from Operations' 5-year high stood at $20.6 million during Q1 2022, with a 5-year trough of -$27.3 million in Q1 2023.
  • Its 5-year average for Cash from Operations is -$15.2 million, with a median of -$17.3 million in 2023.
  • Per our database at Business Quant, Arbutus Biopharma's Cash from Operations skyrocketed by 21531.23% in 2022 and then crashed by 23240.7% in 2023.
  • Over the past 5 years, Arbutus Biopharma's Cash from Operations (Quarter) stood at -$19.6 million in 2021, then grew by 13.34% to -$17.0 million in 2022, then dropped by 1.78% to -$17.3 million in 2023, then surged by 40.35% to -$10.3 million in 2024, then surged by 43.61% to -$5.8 million in 2025.
  • Its Cash from Operations stands at -$5.8 million for Q3 2025, versus -$15.7 million for Q2 2025 and -$13.4 million for Q1 2025.